INTRODUCTION
Historically, high endogenous total testosterone (TT) milieu in men had generally been believed to be the core cardinal agent in the etiopathogenesis of prostate cancer disease. This notion stems from the novel report in 1941 by Huggins and Hodges who proposed that high plasma TT level was the culprit in prostate cancer risk and the various associated adverse clinicopathologic and poor prognostic features of the disease. 1, 2 These adverse features of the disease attributed to high TT includes higher Gleason scores, higher tumor burden, higher metastatic potential, higher biochemical recurrence rate following therapy and a higher serum prostate-specific antigen (PSA) levels. [3] [4] [5] Following that novel report of several decades ago, one of the management modalities of the disease had been hinged on the principle of reduction of TT levels or action using either medical or surgical intervention. challenged and debated. 5 The challenge and debate had surfaced following the observation and report from various epidemiologic studies that low, rather than high, plasma TT level is associated with prostate cancer risk and the various adverse clinicopathologic and poor prognostic features of the disease. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In addition, in support of these studies is the fact that endogenous TT decreases with advancing age at the same time that prostate cancer incidence increases. 6 This recent observation has provoked several authors in various studies to suggest for a review of the decade-long norm of high TT association with prostate cancer. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] However, some other authors have questioned these recent assumptions of low, rather than, TT levels involvement in prostate cancer risk and these various adverse features of the disease. 5 Therefore, the relationship between endogenous TT and prostate cancer continues to be controversial and hence, merits further investigation. 5 This study was therefore designed to evaluate the relationship between TT and PSA in prostate cancer patients to examine the hypothesis that low, rather than high, endogenous TT is associated with adverse prostate cancer features using high-risk total PSA as a marker of the adverse prostate cancer feature.
The specific objectives of the present study are to determine the pattern of gonadal status (hypogonadism and eugonadism) among the study cohorts, to determine the pattern of distribution of total PSA and TT based on gonadal status among the study cohorts and to determine the relationship between total PSA and TT based on gonadal status among the study cohorts.
METHODS
The study was conducted in the Department of Chemical Pathology and Metabolic Medicine of the University of Port Harcourt Teaching Hospital (UPTH), River State, Nigeria. The hospital is a modern tertiary hospital situated in the south-south region of the Niger Delta area of the country providing specialist medical care to the entire populace in the region. The Department of Chemical Pathology and Metabolic Medicine of the hospital is a screening and diagnostic center for various cancers using tumor markers.
It is a retrospective, descriptive, and cross-sectional analysis of total PSA and total TT records of all the prostate cancer patients who had presented to the Department of Chemical Pathology and Metabolic Medicine for serum total PSA and TT investigations as part of their pre-treatment protocols from 1st January 2008 to 31st December 2017. The study was conducted between 1st January and 23rd February 2018. Being a retrospective study, ethical approval and informed consent is not required in UPTH.
Inclusion criteria
• Pretreatment serum total PSA and serum TT records of men with histologically confirmed prostate cancer who had presented to the department during the study period.
Exclusion criteria
• Post-treatment serum total PSA and total TT.
• Pretreatment serum total PSA and serum TT records of histological confirmed prostate cancer patients who had been diagnosed with diabetes mellitus, liver disorders or thyroid disorders, including those already on treatment (medical, surgery or radiotherapy) for prostate cancer, • Those on exogenous TT therapy, and • Those with incomplete data.
Fasting venous whole blood specimen were collected from each patient between 8 am and 10 am daily and processed accordingly to obtain the serum samples for analysis. Laboratory analysis for total PSA and TT was done via enzyme immunoassay methods with reagents procured from Monoblind Incorporated, California, United States of America. Analytical accuracy was monitored with the use of three levels of commercial quality control sera sourced from the same manufacturer. Prostate cancer risk was arbitrarily stratified based on serum total PSA value of <20.0µg/l as low-risk, 20.1-40 µg/l as moderate-risk, and >40.1 µg/l as high-risk. While using the serum TT cutoff value of 12 nmol/l suggested by Bhasin et al to define gonadal status as hypogonadism (TT<12.0 nmol/l) and eugonadism (TT> 12.0 nmol/l). 18 Acquired data were all entered into SPSS version 20, subsequently reviewed, coded, and analyzed accordingly. Data normality was ascertained using Shapiro-Wilk statistical test. Non-parametric distributed data were logtransformed prior to analysis. Continuous data were presented as mean ± standard deviations and compared with independent t-test or one-way analysis of variance (one-way ANOVA) where appropriate, while categorical data were presented in numbers and percentages and compared with Chi-square test. Pearson's correlation test was used to determine relationships between continuous data. A cutoff p-value of < 0.05 was designated as being statistically significant. In Table 1 , the majority (56.7%) of the study cohorts are between 70 to 79 years of age while only 5.3% of the study cohort were below 59 years of age.
In Table 2 , Hypogonadism was observed in 34.7% of the study cohort. These patients with hypogonadism (TT < 12 nmol/l) had higher total PSA values compared to those with eugonadal (TT > 12nmol/l) TT level. In Table 3 , patients with high-risk PSA values (PSA> 40 µg/l) had a lower TT values compared to those in the mild-risk and moderate-risk PSA groups. In Table 4 , there were varying degrees of negative correlation between total PSA and TT within the overall study group, hypogonadal group, eugonadal group, and within the different strata of PSA-based risk groups. However, while every other correlations were statistically significant, that of the mild-risk PSA group was not. The significant negative correlations are stronger among the overall study group, hypogonadism group, and among the high-risk group.
DISCUSSION
For decades following that report of Huggins and Hodges, the influence of high TT on the prostate tissue had been held sacrosanct as one of the culprit in prostate cancer risk, etiopathogenesis, and various adverse clinicopathologic and poor prognostic features of the disease. 1,2 On the basis of that report by Huggins and Hodges, various interventions to reduce endogenous TT or its action on the prostate gland has been one of the main strategies in the treatment of prostate cancer. However, this assumption is currently been challenged as numerous authors have suggested that low, rather high, endogenous testosterone predicts prostate cancer risks and the various associated adverse and poor prognostic features including among others high total PSA levels. 6, 17 In the present study, we have used high total PSA as a marker of poor prognostic feature since it correlates with tumor burden, stage, aggressiveness, metastasis, biochemical recurrence, and Gleason score, and observed that patients with hypogonadism had significantly higher total PSA levels than the eugonadal patients. 19 In addition, those patients with the high-risk PSA level had the lowest TT level compared to patients with mild-risk and moderate-risk PSA levels. These findings suggest that low, rather than high, TT predicts higher PSA level which implies a poor prognostic feature of prostate cancer among the study cohort. In support of this finding is the observed strong negative correlation between PSA and TT among the patients with hypogonadism and highrisk PSA levels. These findings and observations in this study regarding the relationship between PSA and TT are in accord with the findings in similar studies by Alsharef et al, Garcia-Cruz et al, Schatzl et al, and Tu et al. 6, 9, 10, 16 Alsharef et al had investigated the association between serum TT and adverse prognostic features in men with prostate cancer and observed that low serum TT was associated with higher PSA, higher grade, locally advanced and metastatic prostate cancer. However, Alsharef et al had used the serum free testosterone in their study in contrast to the total serum TT employed in this study. Garcia-Cruze et al concluded in their study that prostate cancer patients with low TT have poor prognostic factors and tumor burden before treatment.
Schatzl et al reported in their study that prostate cancer patients with low TT had higher Gleason score compared to those with normal TT. Recently, Tu et al had investigated whether low TT at prostate cancer diagnosis was associated with aggressive prostate cancer and poor outcomes and observed that low TT was associated with aggressive prostate cancer and prostate cancer-specific survival.
The mechanism of low TT-induced adverse clinicopathologic and poor prognostic features in prostate cancer disease is poorly understood. However, Tu et al posit that the low TT milieu in men might activate some oncogenic pathways that select for specific molecular features that are indicative of adverse or poor prognostic outcome. 16 While Loeb et al posit that the high or normal TT levels keep the prostate cells and early prostate cancer cells in a differentiated state and that the loss of this TT function secondary to low serum TT may lead to the development of less-differentiated cancer with adverse and poor prognostic features.
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CONCLUSION
The findings of this study suggest low, rather than high, endogenous testosterone predicts higher PSA in prostate cancer patients. Therefore, low serum testosterone could serve as a biomarker to complement PSA in predicting prostate cancer.
However, further studies are warranted to confirm this association. It is a retrospective hospital-based study conducted in a single center, therefore its conclusion may not reflect the status of the entire population in the region.
